Appendicitis After Initiation of Tirzepatide
Garrett Chan1, Mariam Ansar1, Marlena Klein1,21Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA; 2Cooper Medical School of Rowan University, Camden, New Jersey, USACorrespondence: Garrett Chan, Email chan-garrett@cooperhealth.eduAbstract: Tirzepatide is a GLP1/GIP...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/appendicitis-after-initiation-of-tirzepatide-peer-reviewed-fulltext-article-DMSO |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832570263506518016 |
|---|---|
| author | Chan G Ansar M Klein M |
| author_facet | Chan G Ansar M Klein M |
| author_sort | Chan G |
| collection | DOAJ |
| description | Garrett Chan1, Mariam Ansar1, Marlena Klein1,21Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA; 2Cooper Medical School of Rowan University, Camden, New Jersey, USACorrespondence: Garrett Chan, Email chan-garrett@cooperhealth.eduAbstract: Tirzepatide is a GLP1/GIP receptor agonist that is used to treat type 2 diabetes and promote weight loss. Common side effects of Tirzepatide include nausea, vomiting, and diarrhea. More severe side effects include pancreatitis, cholelithiasis, thyroid cancer, and cholecystitis. With the increased use of these medications, additional side effects are being discovered. Delayed gastric emptying associated with GLP1/GIP receptor agonists can increase the risk of developing appendicitis due to changes in gastrointestinal motility. There is minimal data on the risk of developing appendicitis with Tirzepatide. This novel case report presents a 73-year-old female patient, without typical risk factors or obvious triggers, who developed appendicitis one week following the initiation of Tirzepatide. Once Tirzepatide was stopped, the patient’s symptoms dramatically improved and there was improvement also demonstrated on CT imaging. The patient eventually got an outpatient appendectomy. Appendicitis is not frequently reported as a GLP1/GIP receptor agonist side effect in clinical studies. There seems to be a temporal association between Tirzepatide and the onset of appendicitis. This case report highlights the importance of considering appendicitis as a potential adverse effect of Tirzepatide, a GLP1/GIP receptor agonist.Keywords: GLP1 receptor agonists, GIP receptor agonists, Tirzepatide, appendicitis, diabetes, obesity |
| format | Article |
| id | doaj-art-d149903fc6fe462fa34a5479a7cd81b2 |
| institution | Kabale University |
| issn | 1178-7007 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj-art-d149903fc6fe462fa34a5479a7cd81b22025-02-02T15:59:39ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072025-01-01Volume 1826126599770Appendicitis After Initiation of TirzepatideChan GAnsar MKlein MGarrett Chan1, Mariam Ansar1, Marlena Klein1,21Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA; 2Cooper Medical School of Rowan University, Camden, New Jersey, USACorrespondence: Garrett Chan, Email chan-garrett@cooperhealth.eduAbstract: Tirzepatide is a GLP1/GIP receptor agonist that is used to treat type 2 diabetes and promote weight loss. Common side effects of Tirzepatide include nausea, vomiting, and diarrhea. More severe side effects include pancreatitis, cholelithiasis, thyroid cancer, and cholecystitis. With the increased use of these medications, additional side effects are being discovered. Delayed gastric emptying associated with GLP1/GIP receptor agonists can increase the risk of developing appendicitis due to changes in gastrointestinal motility. There is minimal data on the risk of developing appendicitis with Tirzepatide. This novel case report presents a 73-year-old female patient, without typical risk factors or obvious triggers, who developed appendicitis one week following the initiation of Tirzepatide. Once Tirzepatide was stopped, the patient’s symptoms dramatically improved and there was improvement also demonstrated on CT imaging. The patient eventually got an outpatient appendectomy. Appendicitis is not frequently reported as a GLP1/GIP receptor agonist side effect in clinical studies. There seems to be a temporal association between Tirzepatide and the onset of appendicitis. This case report highlights the importance of considering appendicitis as a potential adverse effect of Tirzepatide, a GLP1/GIP receptor agonist.Keywords: GLP1 receptor agonists, GIP receptor agonists, Tirzepatide, appendicitis, diabetes, obesityhttps://www.dovepress.com/appendicitis-after-initiation-of-tirzepatide-peer-reviewed-fulltext-article-DMSOglp1 receptor agonistsgip receptor agonistsmounjarotirzepatideappendicitisdiabetesobesity |
| spellingShingle | Chan G Ansar M Klein M Appendicitis After Initiation of Tirzepatide Diabetes, Metabolic Syndrome and Obesity glp1 receptor agonists gip receptor agonists mounjaro tirzepatide appendicitis diabetes obesity |
| title | Appendicitis After Initiation of Tirzepatide |
| title_full | Appendicitis After Initiation of Tirzepatide |
| title_fullStr | Appendicitis After Initiation of Tirzepatide |
| title_full_unstemmed | Appendicitis After Initiation of Tirzepatide |
| title_short | Appendicitis After Initiation of Tirzepatide |
| title_sort | appendicitis after initiation of tirzepatide |
| topic | glp1 receptor agonists gip receptor agonists mounjaro tirzepatide appendicitis diabetes obesity |
| url | https://www.dovepress.com/appendicitis-after-initiation-of-tirzepatide-peer-reviewed-fulltext-article-DMSO |
| work_keys_str_mv | AT chang appendicitisafterinitiationoftirzepatide AT ansarm appendicitisafterinitiationoftirzepatide AT kleinm appendicitisafterinitiationoftirzepatide |